Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

• DOI: 10.1186/s13045-021-01190-3
• Publication Date: 2021-10-24T16:02:40Z
• Authors: Lorenzo Canti; Stéphanie Humblet...; Isabelle Desombere; Julika Neumann; Pieter Pannus; Leo Heyndrickx; Aurélie Henry; Sophie Servais; Evelyne Willems; Grégory Ehx; Stanislas Goriely; Laurence Seidel; Johan Michiels; Betty Willems; Adrian Liston; Kevin K. Ariën; Yves Beguin; Maria E. Goossens; Arnaud Marchant; Frédéric Baron
• Keywords: Hematology

Abstract Background Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain be elucidated. Methods Forty allo-HCT were included a study of immunization with BNT162b2 at days 0 and 21. Binding antibodies (Ab) receptor binding domain (RBD) assessed 0, 21, 28, 49 while neutralizing Ab against wild type (NT50) 49. Results observed patients compared those obtained 40 healthy adults naive infection. Flow cytometry analysis peripheral blood cells was performed before vaccination identify potential predictors responses. Three had detectable anti-RBD vaccination. Among the 37 patients, 20 (54%) 32 (86%) 21 postvaccination. Comparing levels adults, we significantly lower 28 Further, 49% versus 88% NT50 day titers than ( P = 0.0004). Ongoing moderate/severe chronic GVHD < 0.01) as well rituximab administration year prior 0.05) correlated low after first multivariate analyses. Compared without or therapy comparable analyses indicated that responses strongly number memory B CD4 + T r > 0.5, more weakly follicular helper 0.4, 0.01). Conclusions Chronic are associated reduced Immunological markers could help risk poor Trial registration The registered clinicaltrialsregister.eu on 11 March 2021 (EudractCT # 2021-000673-83).